Plain-English translation of NCT07527221 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a Phase 1 safety study of ZE74-0282, a new experimental medication. Researchers will give the medication to healthy volunteers at different dose levels to understand how safe it is, how your body processes it, and what effects it has. This is the first time the medication is being tested in humans.
Before any new medication can be tested in patients with a disease, it must first be carefully studied in healthy people to make sure it is safe and to understand how the body handles it. This trial fills that important first step.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will receive a single dose of either the new medication or a placebo (inactive substance) that looks identical. The study is organized in stages, with lower doses tested first and safety checked before moving to higher doses. You will stay at the research clinic for monitoring, have blood drawn, and undergo heart monitoring and other standard medical checks to ensure the medication is safe.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Eilean Therapeutics AU Pty Ltd
Enrollment target
~64 participants
Started
April 2026
Primary completion
November 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ekaterina Dokukina
Eilean Therapeutics AU Pty Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.